March 21, 2022
Life Sciences
  • AstraZeneca announced its antibody-based cocktail to prevent and treat COVID-19 retained neutralizing activity against Omicron COVID-19 variants, including the BA.2 sub-variant. Britain’s drug regulator approved the therapy, called Evusheld, last week for preventing infections in adults with poor immune response. The approval was granted based on trials proving the therapy cut the risk of developing symptomatic COVID-19 by 77 percent. (Article here)